Compile Data Set for Download or QSAR
maximum 50k data
Found 52 Enz. Inhib. hit(s) with all data for entry = 3524
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM402876(US10329303, Example 1)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403253(US10329303, Example 52)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM402974(US10329303, Example 3)
Affinity DataEC50:  5.50E+3nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM402975(US10329303, Example 4)
Affinity DataEC50:  200nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403025(US10329303, Example 5)
Affinity DataEC50:  160nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403040(US10329303, Example 6)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403041(US10329303, Example 7)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403059(US10329303, Example 8)
Affinity DataEC50:  34nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403093(US10329303, Example 9)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403094(US10329303, Example 10)
Affinity DataEC50:  90nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403095(US10329303, Example 11)
Affinity DataEC50:  25nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403109(US10329303, Example 12)
Affinity DataEC50:  75nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403111(US10329303, Example 13)
Affinity DataEC50:  50nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403118(US10329303, Example 14)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403142(US10329303, Example 15)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403155(US10329303, Example 16)
Affinity DataEC50:  220nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403158(US10329303, Example 17)
Affinity DataEC50:  100nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403181(US10329303, Example 18)
Affinity DataEC50:  900nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403182(US10329303, Example 19)
Affinity DataEC50:  70nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403184(US10329303, Example 20)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403188(US10329303, Example 21)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403218(US10329303, Example 22)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403224(US10329303, Example 23)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403225(US10329303, Example 24)
Affinity DataEC50:  1nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403226(US10329303, Example 25)
Affinity DataEC50:  300nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403227(US10329303, Example 26)
Affinity DataEC50:  90nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403228(US10329303, Example 27)
Affinity DataEC50:  80nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403229(US10329303, Example 28)
Affinity DataEC50:  40nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403230(US10329303, Example 29)
Affinity DataEC50:  80nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403231(US10329303, Example 30)
Affinity DataEC50:  600nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403232(US10329303, Example 31)
Affinity DataEC50:  100nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403233(US10329303, Example 32)
Affinity DataEC50:  900nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403234(US10329303, Example 33)
Affinity DataEC50:  70nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403235(US10329303, Example 34)
Affinity DataEC50:  1nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403236(US10329303, Example 35)
Affinity DataEC50:  80nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403237(US10329303, Example 36)
Affinity DataEC50:  100nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403238(US10329303, Example 37)
Affinity DataEC50:  100nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403239(US10329303, Example 38)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403240(US10329303, Example 39)
Affinity DataEC50:  90nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403241(US10329303, Example 40)
Affinity DataEC50:  50nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403242(US10329303, Example 41)
Affinity DataEC50:  800nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403243(US10329303, Example 42)
Affinity DataEC50:  5.50E+3nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403244(US10329303, Example 43)
Affinity DataEC50:  500nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403245(US10329303, Example 44)
Affinity DataEC50:  200nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403246(US10329303, Example 45)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403247(US10329303, Example 46)
Affinity DataEC50:  5.50E+3nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403248(US10329303, Example 47)
Affinity DataEC50:  5.50E+3nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403249(US10329303, Example 48)
Affinity DataEC50:  5.50E+3nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403250(US10329303, Example 49)
Affinity DataEC50:  5.50E+3nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMalignant T-cell-amplified sequence 1(Homo sapiens (human))
The Scripps Research Institute

US Patent
LigandPNGBDBM403251(US10329303, Example 50)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 52 total ) | Next | Last >>
Jump to: